Akari Therapeutics (NASDAQ:AKTX) Posts Quarterly Earnings Results, Misses Estimates By $686.67 EPS

Akari Therapeutics (NASDAQ:AKTX) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($688.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.33) by ($686.67), reports.

Akari Therapeutics Stock Performance

Shares of NASDAQ AKTX traded up $13.13 during midday trading on Friday, reaching $18.27. 33,249,219 shares of the company were exchanged, compared to its average volume of 424,160. The stock’s 50-day moving average price is $5.37 and its 200-day moving average price is $10.53. Akari Therapeutics has a one year low of $3.02 and a one year high of $56.80.

Analyst Ratings Changes

Several analysts recently commented on AKTX shares. Maxim Group cut Akari Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, April 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Akari Therapeutics in a research report on Monday, April 20th. Finally, HC Wainwright lifted their target price on Akari Therapeutics to $27.00 and gave the stock a “buy” rating in a report on Wednesday, April 1st. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $89.00.

Institutional Investors Weigh In On Akari Therapeutics

A hedge fund recently bought a new stake in Akari Therapeutics stock. Armistice Capital LLC bought a new stake in Akari Therapeutics PLC (NASDAQ:AKTX) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 2,723,966 shares of the biopharmaceutical company’s stock, valued at approximately $787,000. Armistice Capital LLC owned about 5.95% of Akari Therapeutics at the end of the most recent reporting period. 5.06% of the stock is owned by institutional investors and hedge funds.

Akari Therapeutics News Roundup

Here are the key news stories impacting Akari Therapeutics this week:

• Positive Sentiment: Akari reported breakthrough preclinical data showing AKTX-101 worked synergistically with KRAS inhibition in pancreatic cancer models, boosting investor optimism about its lead ADC program. Article Title
• Positive Sentiment: Market commentary highlighted the stock’s surge after the cancer-data release, with some traders pointing to possible upside if the platform continues to show promise. Article Title
• Neutral Sentiment: Akari announced a $5.5 million private placement offering to fund development of AKTX-101, providing near-term cash but also signaling dilution risk. Article Title
• Neutral Sentiment: The company also announced an ADS ratio change and reverse split, a corporate action that can alter the share structure and often contributes to trading volatility. Article Title
• Negative Sentiment: Akari’s latest quarterly results missed expectations by a wide margin, underscoring that the company remains highly speculative and financially challenged. Article Title
• Negative Sentiment: Trading in AKTX was halted multiple times for LULD pauses, reflecting extreme intraday volatility as investors reacted to the news flow. Article Title

About Akari Therapeutics

Akari Therapeutics plc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel complement inhibitors for the treatment of inflammatory and immunological diseases. The company’s research centers on modulation of the complement cascade, a key component of the innate immune system, with the goal of delivering targeted therapies to patients suffering from rare and severe disorders.

Akari’s lead pipeline asset is sutimlimab, a humanized monoclonal antibody that selectively inhibits the C1s protein and is being evaluated in pivotal clinical studies for cold agglutinin disease.